Patent ID: 7799773

Claim:
A method of treatment of cognitive impairments in Alzheimer's disease, mild cognitive impairment, age-related memory dysfunction, epilepsy, neuropathic pain, Parkinson's disease, cognitive deficit of schizophrenia, attention deficit hyperactivity disorder, or depression, in a human, which comprises administering to said human, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R 1 represents —C 3-7 cycloalkyl optionally substituted by C 1-3 alkyl; R 2 represents: hydrogen; —C 1-6 alkyl, optionally substituted by a —CO 2 R 4 or —CONR 5 R 6 group; —X—C 3-8 cycloalkyl-Y-heterocyclyl; —X-aryl-Y—C 3-8 cycloalkyl; —X-aryl, optionally substituted by one or two halogen, C 1-6 alkyl, C 1-6 alkoxy, —CO 2 R 4 , —CONR 5 R 6 , —NR 5 COR 6 , —SO 2 NR 5 R 6 or cyano groups; —X-aryl-Y-heterocyclyl, optionally substituted by one or two ═O, halogen or R 4 groups; —X-heteroaryl, optionally substituted by one or two halogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, nitro, hydroxy, —COR 4 , —CO 2 R 4 , —NR 5 R 6 , —NR 5 COR 6 , —CONR 5 R 6 or ═O groups; —X-heteroaryl-Y-aryl, optionally substituted by a C 1-6 alkylsulfonyl or —NR 5 COR 6 group; —X-heteroaryl-Y-heteroaryl, optionally substituted by a C 1-6 alkyl group; —X-heteroaryl-Y-heterocyclyl, optionally substituted by one or two ═O, C 1-6 alkyl, hydroxy, or halogen groups; —X-heterocyclyl, optionally substituted by a C 1-6 alkylsulfonyl, C 1-6 alkoxycarbonyl, —CO 2 R 4 , —COR 4 or —CONR 5 R 6 group; —X-heterocyclyl-Y-aryl, optionally substituted by a halogen, cyano, C 1-6 alkylsulfonyl, R 4 or —CONR 5 R 6 group; —X-heterocyclyl-Y-heterocyclyl, optionally substituted by one or two ═O or R 4 groups; —X-heterocyclyl-Y—C 3-8 cycloalkyl; or —X-heterocyclyl-Y-heteroaryl, optionally substituted by one or two C 1-6 alkyl, ═O, cyano or —CONR 5 R 6 groups; X represents a bond or C 1-6 alkyl; Y represents a bond, C 1-6 alkyl, CO, COC 2-6 alkenyl, O or SO 2 ; R 3 represents halogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, amino or trifluoromethyl; n is 0, 1 or 2; and R 4 , R 5 and R 6 independently represent hydrogen, C 1-6 alkyl, —C 3-8 cycloalkyl, —C 1-6 alkyl-C 3-8 cycloalkyl, aryl, heterocyclyl or heteroaryl or —NR 5 R 6 may represent a nitrogen containing heterocyclyl group, wherein said R 4 , R 5 and R 6 groups may be optionally substituted by 1, 2 or 3 substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, cyano, amino, ═O or trifluoromethyl; and wherein when R 2 represents —X-heterocyclyl, —X-heterocyclyl-Y—C 3-8 cycloalkyl, —X-heterocyclyl-Y-aryl, —X-heterocyclyl-Y-heteroaryl or —X-heterocyclyl-Y-heterocyclyl, said heterocyclyl group is attached to X via a carbon atom.